| Detailed information |
|---|
| CancerLivER ID | 2321 |
| Biomarker | TGF beta |
| Biomarker Name/Symbol (given in Publication) | TGF beta |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Strong predictor for RFS in late-recurring (>1 year) and validated on independent dataset |
| Experimental Condition | early occurrence v/s late recurrence |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upegulated in HCC than non-tumor |
| Level of significance | NA |
| Source | Tissue |
| PMID | 20380719 |
| Type of Biomarker | Prognostic |
| Pathway | Regulates cell proliferation, differentiation and growth |
| Cohort | 90 HCV-associated HCC patients; 44 Nontumoral HCC; 8 metastatic liver tumors |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV associated HCC |
| Year of Publication | 2010 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT01061840,NCT02148562,NCT02947165,NCT00537121,NCT01668381,NCT02423343,NCT02178358,NCT01911273,NCT03203837,NCT01505166,NCT02906397,NCT01972672,NCT00764140,NCT03219372,NCT02267213 |